Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of I-Mab's Felzartamab?
Felzartamab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in IgA Nephropathy (Berger's Disease). According...
Felzartamab by Human Immunology Biosciences for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Felzartamab is under clinical development by Human Immunology Biosciences and currently in Phase II for IgA Nephropathy (Berger's Disease). According...
Felzartamab by MorphoSys for Systemic Lupus Erythematosus: Likelihood of Approval
Felzartamab is under clinical development by MorphoSys and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase...